+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Breast Cancer Liquid Biopsy Market - Global Forecast to 2030- Product Image
Breast Cancer Liquid Biopsy Market - Global Forecast to 2030- Product Image
Sale

Breast Cancer Liquid Biopsy Market - Global Forecast to 2030

  • PDF Icon

    Report

  • 180 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011425
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Breast Cancer Liquid Biopsy Market grew from USD 589.92 million in 2024 to USD 705.85 million in 2025. It is expected to continue growing at a CAGR of 19.49%, reaching USD 1.71 billion by 2030.

Breast cancer remains one of the most pervasive and deadly malignancies affecting women worldwide. Traditional tissue biopsies have long been the gold standard for diagnosis and treatment planning, yet they present limitations in terms of invasiveness, sampling bias, and inability to capture tumor heterogeneity over time. Liquid biopsy has emerged as a minimally invasive alternative, offering the potential to revolutionize early detection, real-time monitoring, and personalized therapeutic strategies. By analyzing biomarkers circulating in body fluids-such as tumor cells, DNA fragments, exosomes, proteins, and vesicles-liquid biopsy enables clinicians and researchers to gain dynamic insights into tumor evolution, therapeutic resistance mechanisms, and risk of recurrence. As technological advancements converge with growing clinical demand, the liquid biopsy market is poised to play a pivotal role in transforming breast cancer management.

Transformative Shifts Shaping the Liquid Biopsy Landscape

Over the past decade, several transformative forces have reshaped the breast cancer liquid biopsy landscape. First, breakthroughs in next-generation sequencing platforms combined with digital PCR and mass spectrometry have dramatically enhanced sensitivity and specificity for detecting rare biomarkers. Concurrently, advances in isolation and detection techniques for circulating tumor cells, DNA, and exosomes have enabled multi-parametric analyses that capture both genetic and proteomic information. Moreover, regulatory bodies worldwide have begun to establish clearer pathways for assay validation, reflecting a growing recognition of liquid biopsy as a companion diagnostic and a tool for post-treatment surveillance. Finally, the rise of patient-centric care models and precision oncology initiatives has accelerated adoption of noninvasive monitoring tools, empowering clinicians to adjust therapeutic regimens in near real time. Together, these shifts are fostering an ecosystem in which collaborative partnerships between technology developers, academic institutions, and pharmaceutical companies drive accelerated commercialization and integration into clinical practice.

Assessing the 2025 US Tariffs Impact on Liquid Biopsy

The implementation of new United States tariffs in 2025 on imported reagents, sequencing instruments, and specialty consumables has introduced headwinds for liquid biopsy developers and service providers. Increased duties on critical reagents used in digital droplet PCR and next-generation sequencing have translated into higher production costs, prompting companies to reevaluate supply chains and consider nearshoring or diversifying vendor portfolios. Instrument manufacturers face margin pressure as tariffs inflate prices for advanced mass spectrometry and rare mutation detection platforms. Although end users may initially absorb these cost increases, long-term reimbursement negotiations could hinge on demonstrating cost-effectiveness against conventional diagnostic methods. Additionally, biotechnology firms developing proprietary assays must weigh the impact of tariffs when planning clinical validation studies, as cross-border collaborations with testing sites in Europe and Asia-Pacific may become more expensive. Despite these challenges, some stakeholders are exploring tariff mitigation strategies-such as redesigning assay chemistries to rely on domestically sourced reagents or entering into joint ventures-to preserve market competitiveness and sustain innovation in liquid biopsy applications.

Key Segmentation Insights for Targeted Market Analysis

A granular segmentation analysis reveals nuanced growth opportunities and technology adoption patterns. Based on test type, circulating tumor cells (CTC) assays are advancing through improved detection and isolation approaches, whereas circulating tumor DNA (ctDNA) platforms leverage next-generation sequencing and PCR-based methods to capture mutational landscapes; exosome analyses, in turn, integrate biomarker profiling with robust isolation workflows. In application, early diagnosis initiatives focus on stage I and II detection, while monitoring treatment response protocols employ sequential testing and therapeutic adjustment frameworks; post-treatment surveillance prioritizes recurrence monitoring algorithms, and treatment selection strategies capitalize on predictive marker analysis. From the end-user perspective, academic institutes drive clinical studies and educational programs, biotechnology and pharmaceutical companies push drug development pipelines, hospitals and clinics integrate assays within general diagnostics and oncology departments, and research institutes spearhead biomarker and cancer-focused investigations. Biomarker type segmentation highlights cell-free DNA assays that detect copy number variations and point mutations; extracellular vesicle evaluations measuring exosomal RNA and protein markers; and protein biomarker tests quantifying growth factors and tumor antigens. Sample type considerations differentiate blood-based assays-distinguishing plasma versus serum workflows-from urine-based exosome analyses. Technology segmentation underscores platforms such as BEAMing for rare mutation detection, digital droplet PCR for quantitative analysis, mass spectrometry for protein quantification, and next-generation sequencing for high-throughput profiling. Sample collection and storage protocols emphasize cryopreservation to maintain sample integrity and pre-analytical processing methods to improve stabilization, whereas development stage classification splits between clinical validation via multi-center trials and experimental trials comprising proof-of-concept studies. Finally, pricing analysis balances cost per test metrics-comparing advanced biomarker panels to routine testing-with evolving reimbursement policies and insurance coverage frameworks.

Regional Dynamics Driving Market Penetration and Growth

Regional dynamics further shape market adoption and investment priorities. In the Americas, robust funding for precision oncology and a supportive regulatory environment expedite commercialization of liquid biopsy assays, with the United States leading pilot programs for early breast cancer detection. Moving eastward, Europe, Middle East & Africa present a heterogeneous landscape: Western Europe benefits from established reimbursement pathways and pan-European collaborative research consortia, while emerging markets in the Middle East and Africa are exploring public-private partnerships to build diagnostic infrastructure. In Asia-Pacific, rapid expansion is driven by rising breast cancer incidence, government initiatives to bolster molecular diagnostics, and local manufacturing of sequencing platforms to reduce reliance on imports, especially in key markets such as China, Japan, India, and Australia. Each region’s unique clinical guidelines, reimbursement frameworks, and healthcare infrastructure will continue to influence the pace and scale of liquid biopsy adoption.

Competitive Landscape: Major Players and Strategic Positions

The competitive landscape is dominated by established diagnostics companies and specialized biotech firms striving to differentiate through assay sensitivity, regulatory approvals, and strategic partnerships. Adaptive Biotechnologies Corporation leverages immune profiling to complement liquid biopsy, while Bio-Rad Laboratories, Inc. offers end-to-end PCR and droplet digital platforms. Biocept, Inc. focuses on CTC and ctDNA assays for real-time disease monitoring, and Biodesix, Inc. integrates proteomic biomarkers for personalized treatment selection. Epic Sciences Inc. provides high-definition CTC analysis, whereas Exact Sciences Corporation expands its early diagnostic portfolio into liquid biopsy. F. Hoffmann-La Roche Ltd. combines proprietary sequencing chemistries with companion diagnostics, and Fluxion Biosciences Inc. develops microfluidic isolation tools. Guardant Health, Inc. pioneers ctDNA-based tests for recurrence risk, while Illumina, Inc. powers high-throughput profiling with its sequencing instruments. Johnson & Johnson Services, Inc. invests in companion diagnostic collaborations, and NeoGenomics Laboratories, Inc. offers comprehensive molecular testing services. Qiagen N.V. by Thermo Fisher Scientific Inc. bridges sample preparation with downstream analysis, whereas Sysmex Corporation commits to automated hematology and CTC workflows. Finally, The Menarini Group targets emerging markets through distribution agreements and local partnerships. These players distinguish themselves by prioritizing regulatory clearances, expanding clinical utility studies, and forging alliances across the diagnostics and pharmaceutical ecosystems.

Actionable Recommendations for Industry Leaders

Industry leaders should pursue a multi-pronged strategy to capitalize on emerging opportunities. First, investing in modular platforms that support both genetic and proteomic biomarker analyses will enable seamless integration into diverse clinical workflows and futureproof assay portfolios against evolving research requirements. Second, establishing strategic partnerships with contract research organizations, hospital networks, and academic consortia can accelerate clinical validation, broaden access to patient cohorts, and strengthen reimbursement dossiers. Third, mitigating tariff-related cost pressures through domestic manufacturing of critical reagents and localizing supply chains will safeguard margin structures and reduce time-to-market vulnerabilities. Fourth, advocating for policy frameworks that recognize the value of noninvasive monitoring-through real-world evidence generation and health economics studies-will be essential for achieving favorable reimbursement and expanding adoption in early diagnosis and post-treatment surveillance. Finally, enhancing end-user education via targeted training programs, digital platforms, and cross-functional workshops will ensure that clinicians and laboratory personnel are proficient in interpreting and acting on liquid biopsy results, thereby maximizing patient outcomes and commercial uptake.

Conclusion: Charting the Future of Liquid Biopsy Solutions

As the breast cancer liquid biopsy market continues to mature, stakeholders who blend technological innovation with strategic partnerships will emerge as winners. Ongoing improvements in assay sensitivity, coupled with expanding clinical evidence, are setting the stage for broader integration into routine oncology care. While tariff fluctuations and reimbursement challenges require proactive management, the underlying demand for minimally invasive diagnostics and dynamic disease monitoring remains strong. Ultimately, the industry’s success will hinge on its ability to demonstrate clear clinical utility, optimize cost-effectiveness, and align with evolving healthcare delivery models. By navigating these complexities with agility and foresight, manufacturers and service providers can solidify liquid biopsy’s role as an indispensable tool in personalized breast cancer management.

Market Segmentation & Coverage

This research report categorizes the Breast Cancer Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Circulating Tumor Cells (CTC)
    • Detection Techniques
    • Isolation Techniques
  • Circulating Tumor DNA (ctDNA)
    • Next-Generation Sequencing
    • PCR-Based Approaches
  • Exosomes
    • Biomarker Analysis
    • Isolation Techniques
  • Early Diagnosis
    • Stage I and II Detection
  • Monitoring Treatment Response
    • Sequential Testing
    • Therapeutic Adjustment
  • Post-Treatment Surveillance
    • Recurrence Monitoring
  • Treatment Selection
    • Predictive Marker Analysis
  • Academic Institutes
    • Clinical Studies
    • Educational Programs
  • Biotechnology and Pharmaceutical Companies
    • Drug Development
  • Hospitals and Clinics
    • General Diagnostics
    • Oncology Departments
  • Research Institutes
    • Biomarker Research
    • Cancer Research
  • Cell-Free DNA
    • Copy Number Variations
    • Point Mutations
  • Extracellular Vesicles
    • Exosomal RNA
    • Protein Markers
  • Protein Biomarkers
    • Growth Factors
    • Tumor Antigens
  • Blood-based Assays
    • Plasma
    • Serum
  • Urine-based Assays
    • Urine Exosomes
  • BEAMing
    • Rare Mutation Detection
  • Digital Droplet PCR
    • Quantitative Analysis
  • Mass Spectrometry
    • Protein Quantification
  • Next-Generation Sequencing
    • High Throughput Profiling
  • Cryopreservation
    • Sample Integrity Maintenance
  • Pre-Analytical Sample Processing
    • Stabilization Methods
  • Clinical Validation
    • Multi-Center Trials
  • Experimental Trials
    • Proof of Concept Studies
  • Cost per Test
    • Advanced Biomarkers
    • Routine Testing
  • Insurance Coverage
    • Reimbursement Policies

This research report categorizes the Breast Cancer Liquid Biopsy Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Breast Cancer Liquid Biopsy Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Adaptive Biotechnologies Corporation
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix, Inc.
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fluxion Biosciences Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • NeoGenomics Laboratories, Inc.
  • Qiagen N. V. by Thermo Fisher Scientific Inc.
  • Sysmex Corporation
  • The Menarini Group

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Breast Cancer Liquid Biopsy Market, by Test Type
8.1. Introduction
8.2. Circulating Tumor Cells (CTC)
8.2.1. Detection Techniques
8.2.2. Isolation Techniques
8.3. Circulating Tumor DNA (ctDNA)
8.3.1. Next-Generation Sequencing
8.3.2. PCR-Based Approaches
8.4. Exosomes
8.4.1. Biomarker Analysis
8.4.2. Isolation Techniques
9. Breast Cancer Liquid Biopsy Market, by Application
9.1. Introduction
9.2. Early Diagnosis
9.2.1. Stage I and II Detection
9.3. Monitoring Treatment Response
9.3.1. Sequential Testing
9.3.2. Therapeutic Adjustment
9.4. Post-Treatment Surveillance
9.4.1. Recurrence Monitoring
9.5. Treatment Selection
9.5.1. Predictive Marker Analysis
10. Breast Cancer Liquid Biopsy Market, by End User
10.1. Introduction
10.2. Academic Institutes
10.2.1. Clinical Studies
10.2.2. Educational Programs
10.3. Biotechnology and Pharmaceutical Companies
10.3.1. Drug Development
10.4. Hospitals and Clinics
10.4.1. General Diagnostics
10.4.2. Oncology Departments
10.5. Research Institutes
10.5.1. Biomarker Research
10.5.2. Cancer Research
11. Breast Cancer Liquid Biopsy Market, by Biomarker Type
11.1. Introduction
11.2. Cell-Free DNA
11.2.1. Copy Number Variations
11.2.2. Point Mutations
11.3. Extracellular Vesicles
11.3.1. Exosomal RNA
11.3.2. Protein Markers
11.4. Protein Biomarkers
11.4.1. Growth Factors
11.4.2. Tumor Antigens
12. Breast Cancer Liquid Biopsy Market, by Sample Type
12.1. Introduction
12.2. Blood-based Assays
12.2.1. Plasma
12.2.2. Serum
12.3. Urine-based Assays
12.3.1. Urine Exosomes
13. Breast Cancer Liquid Biopsy Market, by Technology
13.1. Introduction
13.2. BEAMing
13.2.1. Rare Mutation Detection
13.3. Digital Droplet PCR
13.3.1. Quantitative Analysis
13.4. Mass Spectrometry
13.4.1. Protein Quantification
13.5. Next-Generation Sequencing
13.5.1. High Throughput Profiling
14. Breast Cancer Liquid Biopsy Market, by Sample Collection and Storage
14.1. Introduction
14.2. Cryopreservation
14.2.1. Sample Integrity Maintenance
14.3. Pre-Analytical Sample Processing
14.3.1. Stabilization Methods
15. Breast Cancer Liquid Biopsy Market, by Development Stage
15.1. Introduction
15.2. Clinical Validation
15.2.1. Multi-Center Trials
15.3. Experimental Trials
15.3.1. Proof of Concept Studies
16. Breast Cancer Liquid Biopsy Market, by Pricing Analysis
16.1. Introduction
16.2. Cost per Test
16.2.1. Advanced Biomarkers
16.2.2. Routine Testing
16.3. Insurance Coverage
16.3.1. Reimbursement Policies
17. Americas Breast Cancer Liquid Biopsy Market
17.1. Introduction
17.2. Argentina
17.3. Brazil
17.4. Canada
17.5. Mexico
17.6. United States
18. Asia-Pacific Breast Cancer Liquid Biopsy Market
18.1. Introduction
18.2. Australia
18.3. China
18.4. India
18.5. Indonesia
18.6. Japan
18.7. Malaysia
18.8. Philippines
18.9. Singapore
18.10. South Korea
18.11. Taiwan
18.12. Thailand
18.13. Vietnam
19. Europe, Middle East & Africa Breast Cancer Liquid Biopsy Market
19.1. Introduction
19.2. Denmark
19.3. Egypt
19.4. Finland
19.5. France
19.6. Germany
19.7. Israel
19.8. Italy
19.9. Netherlands
19.10. Nigeria
19.11. Norway
19.12. Poland
19.13. Qatar
19.14. Russia
19.15. Saudi Arabia
19.16. South Africa
19.17. Spain
19.18. Sweden
19.19. Switzerland
19.20. Turkey
19.21. United Arab Emirates
19.22. United Kingdom
20. Competitive Landscape
20.1. Market Share Analysis, 2024
20.2. FPNV Positioning Matrix, 2024
20.3. Competitive Analysis
20.3.1. Adaptive Biotechnologies Corporation
20.3.2. Bio-Rad Laboratories, Inc.
20.3.3. Biocept, Inc.
20.3.4. Biodesix, Inc.
20.3.5. Epic Sciences Inc.
20.3.6. Exact Sciences Corporation
20.3.7. F. Hoffmann-La Roche Ltd.
20.3.8. Fluxion Biosciences Inc.
20.3.9. Guardant Health, Inc.
20.3.10. Illumina, Inc.
20.3.11. Johnson & Johnson Services, Inc.
20.3.12. NeoGenomics Laboratories, Inc.
20.3.13. Qiagen N. V. by Thermo Fisher Scientific Inc.
20.3.14. Sysmex Corporation
20.3.15. The Menarini Group
21. ResearchAI
22. ResearchStatistics
23. ResearchContacts
24. ResearchArticles
25. Appendix
List of Figures
FIGURE 1. BREAST CANCER LIQUID BIOPSY MARKET MULTI-CURRENCY
FIGURE 2. BREAST CANCER LIQUID BIOPSY MARKET MULTI-LANGUAGE
FIGURE 3. BREAST CANCER LIQUID BIOPSY MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE COLLECTION AND STORAGE, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE COLLECTION AND STORAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRICING ANALYSIS, 2024 VS 2030 (%)
FIGURE 24. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRICING ANALYSIS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 26. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 28. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 30. ASIA-PACIFIC BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. BREAST CANCER LIQUID BIOPSY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 34. BREAST CANCER LIQUID BIOPSY MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BREAST CANCER LIQUID BIOPSY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS (CTC), BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DETECTION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ISOLATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS (CTC), 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA (CTDNA), BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PCR-BASED APPROACHES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA (CTDNA), 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ISOLATION TECHNIQUES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STAGE I AND II DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MONITORING TREATMENT RESPONSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SEQUENTIAL TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY THERAPEUTIC ADJUSTMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MONITORING TREATMENT RESPONSE, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST-TREATMENT SURVEILLANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RECURRENCE MONITORING, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST-TREATMENT SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PREDICTIVE MARKER ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EDUCATIONAL PROGRAMS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DRUG DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS AND CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GENERAL DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ONCOLOGY DEPARTMENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CANCER RESEARCH, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COPY NUMBER VARIATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POINT MUTATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMAL RNA, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PROTEIN MARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PROTEIN BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY GROWTH FACTORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TUMOR ANTIGENS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 62. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 63. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BLOOD-BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 64. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 65. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 66. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BLOOD-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 67. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE-BASED ASSAYS, BY REGION, 2018-2030 (USD MILLION)
TABLE 68. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE EXOSOMES, BY REGION, 2018-2030 (USD MILLION)
TABLE 69. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 70. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 71. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, BY REGION, 2018-2030 (USD MILLION)
TABLE 72. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RARE MUTATION DETECTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 73. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, 2018-2030 (USD MILLION)
TABLE 74. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL DROPLET PCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 75. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY QUANTITATIVE ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 76. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL DROPLET PCR, 2018-2030 (USD MILLION)
TABLE 77. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 78. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PROTEIN QUANTIFICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 79. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 80. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 81. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HIGH THROUGHPUT PROFILING, BY REGION, 2018-2030 (USD MILLION)
TABLE 82. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 83. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE COLLECTION AND STORAGE, 2018-2030 (USD MILLION)
TABLE 84. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CRYOPRESERVATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 85. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE INTEGRITY MAINTENANCE, BY REGION, 2018-2030 (USD MILLION)
TABLE 86. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CRYOPRESERVATION, 2018-2030 (USD MILLION)
TABLE 87. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRE-ANALYTICAL SAMPLE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
TABLE 88. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY STABILIZATION METHODS, BY REGION, 2018-2030 (USD MILLION)
TABLE 89. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRE-ANALYTICAL SAMPLE PROCESSING, 2018-2030 (USD MILLION)
TABLE 90. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 91. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CLINICAL VALIDATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 92. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MULTI-CENTER TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 93. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 94. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXPERIMENTAL TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 95. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PROOF OF CONCEPT STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 96. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXPERIMENTAL TRIALS, 2018-2030 (USD MILLION)
TABLE 97. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 98. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COST PER TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 99. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ADVANCED BIOMARKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 100. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ROUTINE TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 101. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COST PER TEST, 2018-2030 (USD MILLION)
TABLE 102. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSURANCE COVERAGE, BY REGION, 2018-2030 (USD MILLION)
TABLE 103. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY REIMBURSEMENT POLICIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 104. GLOBAL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 105. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 106. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS (CTC), 2018-2030 (USD MILLION)
TABLE 107. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA (CTDNA), 2018-2030 (USD MILLION)
TABLE 108. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2030 (USD MILLION)
TABLE 109. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 110. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 111. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MONITORING TREATMENT RESPONSE, 2018-2030 (USD MILLION)
TABLE 112. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST-TREATMENT SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 113. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, 2018-2030 (USD MILLION)
TABLE 114. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 115. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 116. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 117. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 118. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 119. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 120. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, 2018-2030 (USD MILLION)
TABLE 121. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, 2018-2030 (USD MILLION)
TABLE 122. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 123. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 124. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BLOOD-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 125. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 126. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 127. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, 2018-2030 (USD MILLION)
TABLE 128. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL DROPLET PCR, 2018-2030 (USD MILLION)
TABLE 129. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 130. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 131. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE COLLECTION AND STORAGE, 2018-2030 (USD MILLION)
TABLE 132. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CRYOPRESERVATION, 2018-2030 (USD MILLION)
TABLE 133. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRE-ANALYTICAL SAMPLE PROCESSING, 2018-2030 (USD MILLION)
TABLE 134. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 135. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 136. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXPERIMENTAL TRIALS, 2018-2030 (USD MILLION)
TABLE 137. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 138. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COST PER TEST, 2018-2030 (USD MILLION)
TABLE 139. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 140. AMERICAS BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 142. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS (CTC), 2018-2030 (USD MILLION)
TABLE 143. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA (CTDNA), 2018-2030 (USD MILLION)
TABLE 144. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2030 (USD MILLION)
TABLE 145. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 146. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 147. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MONITORING TREATMENT RESPONSE, 2018-2030 (USD MILLION)
TABLE 148. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST-TREATMENT SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 149. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, 2018-2030 (USD MILLION)
TABLE 150. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 151. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 152. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 153. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 154. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 155. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 156. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, 2018-2030 (USD MILLION)
TABLE 157. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, 2018-2030 (USD MILLION)
TABLE 158. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 159. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 160. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BLOOD-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 161. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 162. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 163. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, 2018-2030 (USD MILLION)
TABLE 164. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL DROPLET PCR, 2018-2030 (USD MILLION)
TABLE 165. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 166. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 167. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE COLLECTION AND STORAGE, 2018-2030 (USD MILLION)
TABLE 168. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CRYOPRESERVATION, 2018-2030 (USD MILLION)
TABLE 169. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRE-ANALYTICAL SAMPLE PROCESSING, 2018-2030 (USD MILLION)
TABLE 170. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 171. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 172. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXPERIMENTAL TRIALS, 2018-2030 (USD MILLION)
TABLE 173. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 174. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COST PER TEST, 2018-2030 (USD MILLION)
TABLE 175. ARGENTINA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 176. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 177. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS (CTC), 2018-2030 (USD MILLION)
TABLE 178. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA (CTDNA), 2018-2030 (USD MILLION)
TABLE 179. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2030 (USD MILLION)
TABLE 180. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 181. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 182. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MONITORING TREATMENT RESPONSE, 2018-2030 (USD MILLION)
TABLE 183. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST-TREATMENT SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 184. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, 2018-2030 (USD MILLION)
TABLE 185. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 186. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 187. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 188. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 189. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 190. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 191. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, 2018-2030 (USD MILLION)
TABLE 192. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, 2018-2030 (USD MILLION)
TABLE 193. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 194. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 195. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BLOOD-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 196. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 197. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 198. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, 2018-2030 (USD MILLION)
TABLE 199. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL DROPLET PCR, 2018-2030 (USD MILLION)
TABLE 200. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 201. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 202. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE COLLECTION AND STORAGE, 2018-2030 (USD MILLION)
TABLE 203. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CRYOPRESERVATION, 2018-2030 (USD MILLION)
TABLE 204. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRE-ANALYTICAL SAMPLE PROCESSING, 2018-2030 (USD MILLION)
TABLE 205. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 206. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 207. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXPERIMENTAL TRIALS, 2018-2030 (USD MILLION)
TABLE 208. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 209. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COST PER TEST, 2018-2030 (USD MILLION)
TABLE 210. BRAZIL BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 211. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 212. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS (CTC), 2018-2030 (USD MILLION)
TABLE 213. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA (CTDNA), 2018-2030 (USD MILLION)
TABLE 214. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2030 (USD MILLION)
TABLE 215. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 217. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MONITORING TREATMENT RESPONSE, 2018-2030 (USD MILLION)
TABLE 218. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST-TREATMENT SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 219. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, 2018-2030 (USD MILLION)
TABLE 220. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 221. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 222. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 223. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 224. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 225. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 226. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, 2018-2030 (USD MILLION)
TABLE 227. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, 2018-2030 (USD MILLION)
TABLE 228. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 229. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 230. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BLOOD-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 231. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 232. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 233. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, 2018-2030 (USD MILLION)
TABLE 234. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL DROPLET PCR, 2018-2030 (USD MILLION)
TABLE 235. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 236. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 237. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE COLLECTION AND STORAGE, 2018-2030 (USD MILLION)
TABLE 238. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CRYOPRESERVATION, 2018-2030 (USD MILLION)
TABLE 239. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRE-ANALYTICAL SAMPLE PROCESSING, 2018-2030 (USD MILLION)
TABLE 240. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 241. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 242. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXPERIMENTAL TRIALS, 2018-2030 (USD MILLION)
TABLE 243. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 244. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COST PER TEST, 2018-2030 (USD MILLION)
TABLE 245. CANADA BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 246. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 247. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS (CTC), 2018-2030 (USD MILLION)
TABLE 248. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA (CTDNA), 2018-2030 (USD MILLION)
TABLE 249. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2030 (USD MILLION)
TABLE 250. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 251. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 252. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MONITORING TREATMENT RESPONSE, 2018-2030 (USD MILLION)
TABLE 253. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST-TREATMENT SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 254. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, 2018-2030 (USD MILLION)
TABLE 255. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 256. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 257. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 258. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 259. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 260. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 261. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, 2018-2030 (USD MILLION)
TABLE 262. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, 2018-2030 (USD MILLION)
TABLE 263. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 264. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 265. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BLOOD-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 266. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY URINE-BASED ASSAYS, 2018-2030 (USD MILLION)
TABLE 267. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 268. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BEAMING, 2018-2030 (USD MILLION)
TABLE 269. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DIGITAL DROPLET PCR, 2018-2030 (USD MILLION)
TABLE 270. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MASS SPECTROMETRY, 2018-2030 (USD MILLION)
TABLE 271. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY NEXT-GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 272. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE COLLECTION AND STORAGE, 2018-2030 (USD MILLION)
TABLE 273. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CRYOPRESERVATION, 2018-2030 (USD MILLION)
TABLE 274. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRE-ANALYTICAL SAMPLE PROCESSING, 2018-2030 (USD MILLION)
TABLE 275. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 276. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CLINICAL VALIDATION, 2018-2030 (USD MILLION)
TABLE 277. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXPERIMENTAL TRIALS, 2018-2030 (USD MILLION)
TABLE 278. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PRICING ANALYSIS, 2018-2030 (USD MILLION)
TABLE 279. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY COST PER TEST, 2018-2030 (USD MILLION)
TABLE 280. MEXICO BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY INSURANCE COVERAGE, 2018-2030 (USD MILLION)
TABLE 281. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TEST TYPE, 2018-2030 (USD MILLION)
TABLE 282. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR CELLS (CTC), 2018-2030 (USD MILLION)
TABLE 283. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CIRCULATING TUMOR DNA (CTDNA), 2018-2030 (USD MILLION)
TABLE 284. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXOSOMES, 2018-2030 (USD MILLION)
TABLE 285. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 286. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EARLY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 287. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY MONITORING TREATMENT RESPONSE, 2018-2030 (USD MILLION)
TABLE 288. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY POST-TREATMENT SURVEILLANCE, 2018-2030 (USD MILLION)
TABLE 289. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY TREATMENT SELECTION, 2018-2030 (USD MILLION)
TABLE 290. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 291. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY ACADEMIC INSTITUTES, 2018-2030 (USD MILLION)
TABLE 292. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOTECHNOLOGY AND PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 293. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY HOSPITALS AND CLINICS, 2018-2030 (USD MILLION)
TABLE 294. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2030 (USD MILLION)
TABLE 295. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
TABLE 296. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY CELL-FREE DNA, 2018-2030 (USD MILLION)
TABLE 297. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY EXTRACELLULAR VESICLES, 2018-2030 (USD MILLION)
TABLE 298. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY PROTEIN BIOMARKERS, 2018-2030 (USD MILLION)
TABLE 299. UNITED STATES BREAST CANCER LIQUID BIOPSY MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 300. UNITED STATES BREA

Companies Mentioned

  • Adaptive Biotechnologies Corporation
  • Bio-Rad Laboratories, Inc.
  • Biocept, Inc.
  • Biodesix, Inc.
  • Epic Sciences Inc.
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fluxion Biosciences Inc.
  • Guardant Health, Inc.
  • Illumina, Inc.
  • Johnson & Johnson Services, Inc.
  • NeoGenomics Laboratories, Inc.
  • Qiagen N. V. by Thermo Fisher Scientific Inc.
  • Sysmex Corporation
  • The Menarini Group

Methodology

Loading
LOADING...

Related Topics

Related Reports

Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast to 2030 - Product Image

Breast Cancer Liquid Biopsy Testing Devices Market - Global Forecast to 2030

  • Report
  • 193 Pages
  • Global
From
Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report by Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), Application, Region, and Segment Forecasts, 2025-2030 - Product Image

Breast Cancer Liquid Biopsy Market Size, Share & Trends Analysis Report by Circulating Biomarkers (Circulating Tumor Cells, Circulating Cell-free DNA, Extracellular Vesicles), Application, Region, and Segment Forecasts, 2025-2030

  • Report
  • 120 Pages
  • Global
From
Breast Cancer Liquid Biopsy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032 - Product Image

Breast Cancer Liquid Biopsy Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2024 To 2032

  • Report
  • 179 Pages
  • Global
From
Breast Cancer Liquid Biopsy Market Report by Product Services, End User, and Region 2024-2032 - Product Image

Breast Cancer Liquid Biopsy Market Report by Product Services, End User, and Region 2024-2032

  • Report
  • 142 Pages
  • Global
From
Breast Cancer Liquid Biopsy Testing Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F - Product Image

Breast Cancer Liquid Biopsy Testing Devices Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F

  • Report
  • 180 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.